PL441204A1 - Cząsteczki siRNA wobec ludzkiej tenascyny-C (TNC), nanocząstki lipidowe LNP i kompozycje farmaceutyczne je obejmujące oraz kompozycje farmaceutyczne do zastosowania w terapii i/lub zapobieganiu rozwoju nowotworu, szczególnie glejaka, raka piersi, raka jajnika, raka trzustki - Google Patents

Cząsteczki siRNA wobec ludzkiej tenascyny-C (TNC), nanocząstki lipidowe LNP i kompozycje farmaceutyczne je obejmujące oraz kompozycje farmaceutyczne do zastosowania w terapii i/lub zapobieganiu rozwoju nowotworu, szczególnie glejaka, raka piersi, raka jajnika, raka trzustki

Info

Publication number
PL441204A1
PL441204A1 PL441204A PL44120422A PL441204A1 PL 441204 A1 PL441204 A1 PL 441204A1 PL 441204 A PL441204 A PL 441204A PL 44120422 A PL44120422 A PL 44120422A PL 441204 A1 PL441204 A1 PL 441204A1
Authority
PL
Poland
Prior art keywords
cancer
pharmaceutical compositions
tnc
lipid nanoparticles
sirna molecules
Prior art date
Application number
PL441204A
Other languages
English (en)
Other versions
PL248228B1 (pl
Inventor
Katarzyna Monika ROLLE
Dariusz Józef WAWRZYNIAK
Michał Julian PRENDECKI
Małgorzata GRABOWSKA
Aleksandra Joanna GRZANKA
Daria Magdalena STUBE
Agnieszka Marta CHABOWSKA-KITA
Łukasz Leszek PRZYBYŁ
Original Assignee
Medicofarma Biotech Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicofarma Biotech Spółka Akcyjna filed Critical Medicofarma Biotech Spółka Akcyjna
Priority to PL441204A priority Critical patent/PL248228B1/pl
Priority to PCT/PL2023/050034 priority patent/WO2023224499A2/en
Priority to US18/866,276 priority patent/US20250340875A1/en
Priority to EP23734763.8A priority patent/EP4526449A2/en
Publication of PL441204A1 publication Critical patent/PL441204A1/pl
Publication of PL248228B1 publication Critical patent/PL248228B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia są cząsteczki siRNA wobec sekwencji transkryptu ludzkiej tenascyny-C (TNC), nanocząstki lipidowe LNP obejmujące takie siRNA, kompozycje farmaceutyczne zawierające takie siRNA i ich mieszaniny oraz kompozycje farmaceutyczne o właściwościach przeciwnowotworowych zawierające takie cząsteczki siRNA w nanocząstkach lipidowych LNP do zastosowania w terapii i/lub zapobieganiu rozwoju nowotworu chrakteryzującego się zwiększoną ekspresją tenascyny-C (TNC) u człowieka, korzystnie wybranego z glejaka, raka piersi, raka jajnika, raka trzustki poprzez hamowanie ekspresji ludzkiej tenascyny-C (TNC).
PL441204A 2022-05-17 2022-05-17 Cząsteczka siRNA wobec sekwencji transkryptu ludzkiej tenascyny- C (TNC), nanocząstka lipidowa LNP i kompozycja farmaceutyczna ją zawierające oraz ich zastosowanie w terapii i/lub zapobieganiu rozwojowi nowotworu glejaka PL248228B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL441204A PL248228B1 (pl) 2022-05-17 2022-05-17 Cząsteczka siRNA wobec sekwencji transkryptu ludzkiej tenascyny- C (TNC), nanocząstka lipidowa LNP i kompozycja farmaceutyczna ją zawierające oraz ich zastosowanie w terapii i/lub zapobieganiu rozwojowi nowotworu glejaka
PCT/PL2023/050034 WO2023224499A2 (en) 2022-05-17 2023-05-17 Sirna molecule against human tenascin-c (tnc) and a pharmaceutical composition comprising it
US18/866,276 US20250340875A1 (en) 2022-05-17 2023-05-17 Sirna molecule against human tenascin-c (tnc) and a pharmaceutical composition comprising it
EP23734763.8A EP4526449A2 (en) 2022-05-17 2023-05-17 Sirna molecule against human tenascin-c (tnc) and a pharmaceutical composition comprising it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441204A PL248228B1 (pl) 2022-05-17 2022-05-17 Cząsteczka siRNA wobec sekwencji transkryptu ludzkiej tenascyny- C (TNC), nanocząstka lipidowa LNP i kompozycja farmaceutyczna ją zawierające oraz ich zastosowanie w terapii i/lub zapobieganiu rozwojowi nowotworu glejaka

Publications (2)

Publication Number Publication Date
PL441204A1 true PL441204A1 (pl) 2023-11-20
PL248228B1 PL248228B1 (pl) 2025-11-12

Family

ID=88838743

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441204A PL248228B1 (pl) 2022-05-17 2022-05-17 Cząsteczka siRNA wobec sekwencji transkryptu ludzkiej tenascyny- C (TNC), nanocząstka lipidowa LNP i kompozycja farmaceutyczna ją zawierające oraz ich zastosowanie w terapii i/lub zapobieganiu rozwojowi nowotworu glejaka

Country Status (1)

Country Link
PL (1) PL248228B1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241323A1 (en) * 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
WO2011107586A1 (en) * 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
US20200222332A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241323A1 (en) * 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
WO2011107586A1 (en) * 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
US20200222332A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLA B. ROCES I IN.: "Pharmaceutics, 2020, 12(11), 1095;", MANUFACTURING CONSIDERATIONS FOR THE DEVELOPMENT OF LIPID NANOPARTICLES USING MICROFLUIDICS, DOI: https://doi.org/10.3390/pharmaceutics12111095 *
FU ZHENG I IN.: "Cell Res.; 2021, 31: 631–648", IN VIVO SELF-ASSEMBLED SMALL RNAS AS A NEW GENERATION OF RNAI THERAPEUTICS, DOI: https://doi.org/10.1038/s41422-021-00491-z *

Also Published As

Publication number Publication date
PL248228B1 (pl) 2025-11-12

Similar Documents

Publication Publication Date Title
MX2023013084A (es) Inhibidores de ras para el tratamiento del cancer.
ZA202402878B (en) Ras inhibitors
MX2024015215A (es) Inhibidores macrociclicos de ras
MX2023013085A (es) Inhibidores de ras.
MX2025011947A (es) Inhibidores macrociclicos de ras
CR20230165A (es) Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
MX2025012575A (es) Inhibidores de ras
Carbonetti et al. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth
Eftekhari et al. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line
Nguyen et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis
PH12022550988A1 (en) Ras inhibitors
PH12022550973A1 (en) Ras inhibitors
He et al. Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer
CL2025003696A1 (es) Compuestos macrocíclicos inhibidores de ras y su uso para tratar cáncer.
Bieg et al. Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
ZA201907225B (en) Treatment of her2 positive cancers
Xu et al. HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cell‐Like Properties
RU2011146654A (ru) Способы лечения рака яичников с применением конъюгированного средства
GEP20267876B (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
Wu et al. β-Lapachone Induces NAD (P) H: Quinone Oxidoreductase-1–and Oxidative Stress–Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis
MX2023015149A (es) Conjugados de fármacos peptídicos.
Huang et al. Ferroptosis-inducing compounds synergize with docetaxel to overcome chemoresistance in docetaxel-resistant non-small cell lung cancer cells
Rimoldi et al. Uptake-release by MSCs of a cationic platinum (II) complex active in vitro on human malignant cancer cell lines
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2